Search
for
Sort by
Research 31–60 of 1000+
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
- Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
- BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
- P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO)
- Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
- When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
- BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
- Comparison of Trichoscopic Features of Alopecia Areata before and after Treatment with Intralesional Steroids
- Platelet-Rich Plasma in Alopecia Areata—A Steroid-Free Treatment Modality: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
- Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
- Management of male pattern hair loss (androgenic alopecia) through Ayurveda multimodal approach: A case report
- Tissue Retinol‐Binding Protein 4 Expression and Its Genetic Variants (rs3758539) in Patients With Severe and Treatment‐Refractory Alopecia Areata: Association With Response to Baricitinib
- Nemolizumab Treatment for Severe Atopic Dermatitis Led to the Simultaneous Improvement of Coexisting Refractory Alopecia Areata: A Case Report
- Table 1_Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study.docx
- Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecial Totalis and Alopecia Universalis: A Randomized, Double-Blind, Placebo-Controlled Trial
- Extensive alopecia areata: Not necessarily recalcitrant to therapy!
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation
- Evaluation of SALT score severity in correlation with trichoscopic findings in alopecia areata: a study of 303 patients
- Effect of Optimal Mixing Ratio of Dendropanax, Sea Salt, and Other Extracts on the Alleviation of Hair Loss Symptoms
- The Application of Radiochemical Techniques to the Study of the Interaction of Hair Fibers with Aqueous Solutions
- Efficacy of systemic minoxidil and tofacitinib combination in treatment‐resistant alopecia universalis
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Evaluation of fractional carbon dioxide laser alone versus its combination with betamethasone valerate in treatment of alopecia areata, a clinical and dermoscopic study
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata